Promising pre-clinical data on TG1050 presented at EASL 2013
Pre-clinical data on TG1050 was presented at EASL 2013, which took place in Amsterdam
Promising pre-clinical data on the novel immunotherapeutic TG1050 to treat chronic hepatitis B infection was presented at the European Association for the Study of the Liver Conference (EASL).
That is according to a statement from the biopharmaceutical organisation Transgene, which develops targeted immunotherapy products to treat those with cancer and chronic infectious diseases.
TG1050 is based on a non-replicative Adenovirus 5 vector that encodes three hepatitis B virus (HBV) antigens or related domains.
Chief executive of Transgene, Phillippe Archinard, revealed he was excited that TG1050 was chosen to be presented at this year's EASL in Amsterdam.
He said: "We hope that this presentation will trigger interest in the scientific community as well as discussions with potential partners."
Indeed, Mr Archinard hopes to begin the first-in-human/phase 1 clinical trial next year.
The presentation provided the most up-to-date data that demonstrated the capacity of TG1050 to induce long-lasting HBV-specific memory T cells.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance